RE:RE:RE:RE:RE:The full article published yesterday Drug development cost money and takes time. Many failures during all the stages but those who cross the finish lines especially for an unmet deadly condition will be rewarded. THTX doesn't have the resources to advance alone either Sort1 or NASH assets, they clearly have realized the need for a partner with resources after completing the part3 of phase1 ontology trial and for the phase2b/3 NASH trial. So any favourable results from the current phase1 oncology trial together with all the preclinical studies and the possiblity of a combo treatment add therapeutic value to the platform and make it more investable for potential partners. One could say the same things about NASH.with the new findings from the sub analysis of the previous trials. Does anyone believe the current valuation is including any of those possibilities( partnerships)? I don't think so. What are the chances of favourable outcomes from the current oncology trial followed by a partnership? Well it can't be zero. The way I see it the expectation of any success ( monetization of their assets) among investors with the current valuation is almost zero.